Validation over design: Avoiding pharmaceutical packaging failure

When validation requirements are overlooked during the design phase, the result can be costly redesigns, failed qualification activities, regulatory findings, and even product recalls. Issues such as material incompatibility, seal failures, labelling errors and environmental vulnerabilities often emerge only when packaging systems are tested against GMP requirements.

A validation-first approach helps manufacturers identify risks early, make informed design decisions, and build packaging systems that can consistently demonstrate performance. In an industry where compliance and patient safety are paramount, the key question is not simply whether a package looks or performs well, but whether it can be validated reliably and maintained in a validated state.

In this blog, we explore the common causes of pharmaceutical packaging failure and how manufacturers can embed validation into packaging design from the outset to support compliance, quality, and patient safety.

The role of validation in pharmaceutical packaging

In UK pharmaceutical manufacturing, validation is a core requirement of UK GMP as enforced by the Medicines and Healthcare products Regulatory Agency. It is the documented process of demonstrating that a packaging system consistently performs as intended and continues to protect product quality throughout its lifecycle.

Validation is typically structured across three stages:

• Installation Qualification (IQ): Confirms equipment and packaging systems are installed correctly and meet specification.
• Operational Qualification (OQ): Verifies equipment operates reliably within defined parameters.
• Performance Qualification (PQ): Demonstrates consistent performance under routine production conditions in a real manufacturing environment.

For pharmaceutical manufacturers, the challenge is not just meeting these requirements, but ensuring that packaging decisions made early in the process support successful validation later. Material selection, component compatibility, and packaging format all have a direct impact on whether a system can be qualified without costly redesigns or delays.

From a UK regulatory perspective, validation must demonstrate that packaging consistently protects product quality and patient safety.

This includes maintaining control over:

• Material and component compatibility
• Seal integrity and pack robustness
• Labelling accuracy and traceability
• Environmental performance during storage and distribution

For companies like Swiftpak working closely with pharmaceutical manufacturers, the focus is increasingly on helping customers make packaging choices that are validation-ready from the outset. This reduces the risk of failure during qualification, improves compliance confidence, and helps ensure packaging systems perform reliably in real-world conditions, not just on paper.

Common causes of pharma packaging failure

Even well-designed pharmaceutical packaging systems can fail during validation or routine production if critical risks are not addressed early in development.

Common causes include:

• Material incompatibility: Issues with blister films, inks, adhesives, or coatings that can affect product stability, legibility, or structural performance.
• Seal integrity failures: Weak seals, leaks, or delamination that compromise product protection and shelf life.
• Labelling errors: Misprints, mix-ups, or traceability failures that create a risk of product misidentification or recall.
• Environmental sensitivity: Packaging that is unable to withstand humidity, temperature changes, or light exposure during storage and distribution.
• Human factors in packaging operations: Errors introduced during line setup, changeovers, or manual handling that can impact consistency and compliance.

From a validation perspective, these issues highlight why packaging decisions must be made with process control and compliance in mind from the outset, not just functional performance or visual design.

Design-first vs validation-first thinking

In pharmaceutical packaging, the order in which decisions are made can determine whether a system passes validation smoothly or becomes a source of costly delay and redesign.

The pitfalls of design-first thinking

When packaging is designed primarily around aesthetics, functionality, or commercial preference, validation requirements can be overlooked. This often leads to systems that are difficult to qualify or fail to demonstrate consistent performance under GMP conditions.

How design decisions can create challenges

Early design choices can unintentionally lock manufacturers into systems that are hard to test, control, or justify, such as:

• Materials with limited or inconsistent qualification data
• Complex pack formats that introduce unnecessary variability
• Processes that rely heavily on manual intervention
• Components that are difficult to standardise or trace

The cost of validation failure

In many cases, issues are only identified during IQ/OQ/PQ activities, leading to:

• Packaging redesigns after failed qualification runs
• Delays to product launch or batch release
• Additional supplier changes and revalidation work

A validation-first approach reframes packaging decisions around a simple but critical question: can this be validated reliably and maintained in a controlled state?

This shift helps ensure packaging systems are not only fit for purpose, but also sustainable within regulated framework.

Building validation into packaging design from the start

Embedding validation early in pharmaceutical packaging design helps reduce risk and avoids costly redesign later. In UK GMP environments, validation should be treated as a core design input rather than a final check.

• Early-stage risk assessment (FMEA): Identify potential failure modes early, including seal integrity, material compatibility, and labelling risks, so they can be designed out before validation.
• Defining critical quality attributes (CQAs): Establish key packaging requirements such as barrier performance, seal strength, traceability, and labelling accuracy to guide design decisions.
• Materials and format selection: Choose well-characterised, proven materials and pack formats that are easier to qualify and more robust during validation testing.
• Supplier qualification and documentation: Work with suppliers who can provide full technical data, change control transparency, and validation-ready documentation to support compliance.

A validation-led approach at the design stage improves consistency, reduces validation failure risk, and supports smoother regulatory approval.

Regulatory expectations and audit readiness

In UK pharmaceutical manufacturing, packaging validation must demonstrate clear, controlled, and repeatable performance in line with expectations from the Medicines and Healthcare products Regulatory Agency under UK GMP.

• What inspectors look for in validation records: Clear evidence that packaging systems have been qualified through IQ/OQ/PQ, with defined acceptance criteria, approved protocols, and traceable results.
• Data integrity and traceability: Records must be complete, contemporaneous, and attributable, with full traceability across materials, batches, and packaging operations.
• Common audit findings: Gaps in validation documentation, unclear change control for packaging components, inconsistent labelling controls, and insufficient evidence of ongoing process verification.
• Documentation best practice: Maintain structured, version-controlled validation files, ensure alignment between protocols and executed records, and keep supplier documentation readily accessible for inspection.

Strong audit readiness depends on maintaining packaging systems in a continuously controlled and well-documented validated state, not just passing initial qualification.

Technology and innovation vs validation complexity

As pharmaceutical packaging continues to evolve, technologies such as smart packaging, serialisation, and track-and-trace systems are becoming increasingly common. These solutions improve visibility across the supply chain, strengthen product authentication, and support regulatory compliance, particularly where end-to-end traceability is required.

Smart packaging and serialisation

Enable unique identification and verification of individual packs, supporting anti-counterfeiting measures and regulatory traceability requirements.

Track-and-trace systems

Improve supply chain visibility and help ensure product authenticity but require tightly controlled data integrity and system validation.

Balancing innovation with control

While digital and automated systems improve efficiency, they must be designed within a validated framework to ensure consistent performance and regulatory compliance.

At Swiftpak, pharmaceutical packaging solutions are developed with this balance in mind, supporting innovation while ensuring systems remain practical to validate, implement and maintain in GMP environments.

Validation is the foundation, not the final step

Validation should never be treated as a final hurdle in pharmaceutical packaging. In UK GMP environments governed by the Medicines and Healthcare products Regulatory Agency, it is a core design constraint that shapes decisions from the earliest stages of development, not a checkbox at the end of a project.

When validation is embedded into packaging design from the outset, organisations benefit from:

• Reduced risk of costly recalls and packaging failures
• Stronger compliance and inspection readiness
• Improved consistency across production and supply chains
• Greater assurance of patient safety and product integrity

Ultimately, the most effective packaging strategies are those that are designed with validation in mind at every stage. If a system cannot be validated reliably and maintained in a controlled state, it should not be progressed into production.

For pharmaceutical manufacturers looking to reduce validation risk and strengthen packaging performance, Swiftpak works in partnership to deliver pharmaceutical packaging solutions designed for compliance from the start.